Minocycline hydrochloride CAS:52-66-4

DL-Penicillamine finds its primary application in the treatment of Wilson's disease, a rare inherited disorder causing copper buildup in vital organs. In this condition, DL-Penicillamine acts as a copper-chelating agent, facilitating the removal of excess copper from the body, thereby preventing organ damage and neurological complications. Additionally, DL-Penicillamine is utilized in the management of rheumatoid arthritis, where it functions as a disease-modifying antirheumatic drug (DMARD). By suppressing immune activity and reducing inflammation, DL-Penicillamine helps alleviate joint pain and stiffness associated with rheumatoid arthritis, thereby improving mobility and quality of life for affected individuals. Furthermore, DL-Penicillamine is prescribed for cystinuria, a genetic disorder characterized by the formation of cystine kidney stones. By binding with cystine, DL-Penicillamine forms soluble complexes, which are more easily excreted in the urine, thereby reducing the risk of stone formation and preventing renal complications. However, DL-Penicillamine usage requires careful monitoring due to its potential for adverse effects, including gastrointestinal disturbances, skin rashes, and hematological abnormalities. Patients should adhere strictly to prescribed dosages and undergo regular medical supervision to ensure optimal therapeutic outcomes while minimizing risks associated with treatment.